Lisata Therapeutics Reveals Promising Phase 2 Trial Data

The latest update is out from Lisata Therapeutics ( (LSTA) ).

On June 26, 2025, Lisata Therapeutics announced promising preliminary data from the Phase 2 ASCEND trial evaluating certepetide in combination with standard-of-care chemotherapy for metastatic pancreatic cancer. The trial’s Cohort B data showed significant improvements in progression-free survival and objective response rates for the certepetide-treated group compared to the placebo group, reinforcing the potential of certepetide as a novel treatment for pancreatic cancer. These findings were presented at the European Society for Medical Oncology Gastrointestinal Cancers Congress in Barcelona, Spain, and suggest a meaningful advancement in the treatment landscape for this aggressive cancer.

The most recent analyst rating on (LSTA) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Lisata Therapeutics stock, see the LSTA Stock Forecast page.

Spark’s Take on LSTA Stock

According to Spark, TipRanks’ AI Analyst, LSTA is a Neutral.

Lisata Therapeutics is navigating through financial difficulties with persistent losses and negative cash flows. The stock’s technical indicators and valuation reflect a challenging financial position. However, recent advancements in clinical trials and regulatory achievements offer potential upside, albeit with high risk.

To see Spark’s full report on LSTA stock, click here.

More about Lisata Therapeutics

Lisata Therapeutics is a clinical-stage pharmaceutical company focused on discovering, developing, and commercializing innovative therapies for advanced solid tumors and other major diseases. Their investigational drug, certepetide, is designed to enhance the delivery and effectiveness of anti-cancer drugs by targeting solid tumors more effectively.

Average Trading Volume: 12,687

Technical Sentiment Signal: Sell

Current Market Cap: $21.67M

See more insights into LSTA stock on TipRanks’ Stock Analysis page.